IRX 2

DRUG2 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, Providence Health & Services

Conditions

Breast CancerBreast NeoplasmsMetastatic CancerNSCLCNon-Small Cell Lung CancerRecurrent CancerRenal Cell CarcinomaSolid Tumor

Phase 1

IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors

CompletedNCT03758781

H. Lee Moffitt Cancer Center and Research InstituteMetastatic Cancer, Non-Small Cell Lung Cancer, NSCLC +6

Start: 2019-02-13End: 2021-08-11Updated: 2023-04-14

Phase 2

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Active, not recruitingNCT04373031

Providence Health & ServicesBreast Cancer, Breast Neoplasms

Start: 2020-12-30End: 2026-12-01Updated: 2026-04-24

Related Papers

Abstract PO2-03-10: Association of pathologic complete response with the 27-gene IO score and week 3 IOpath response following neoadjuvant pembrolizumab +/- intralymphatic cytokines in the neoIRX trial

Cancer Research2024-05-02

NeoIRX trial: Immunologic induction with peri-lymphatic cytokines to enhance pembrolizumab (pembro) response in stage II/III triple-negative breast cancer (TNBC).

Journal of Clinical Oncology2023-06-013 citations

Abstract OT1-18-03: The neoIRX trial:locoregional cytokine therapy to promote immunologic priming and enhanced response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC)

Cancer Research2022-02-151 citations

398 neoIRX: a phase II trial of locoregional cytokine therapy to promote immunologic priming and clinical response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC)

Regular and Young Investigator Award Abstracts2021-11-01

Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer

Breast Cancer Research2021-01-0766 citations

The IRX-2 regimen combined with nivolumab in recurrent/metastatic solid tumors: A phase 1b study to evaluate the safety, determine recommended phase 2 dose (RP2D), and investigate the biologic and clinical activity.

Journal of Clinical Oncology2019-05-201 citations